Becoming a Better Investor: Why I Bought Abbott and Exxon

Before you go, we thought you'd like these...
Before you go close icon

The following video is part of our "Motley Fool Conversations" series, in which Senior Technology Editor Eric Bleeker and fellow Fool Maggie Muraca discuss topics across the investing world.

One of The Motley Fool's company goals this year has been to get all of its employees investing and learning about how to secure their financial future. In this edition of the series, Eric Bleeker talks to Maggie Muraca, a marketing employee, to get more background on her decision to begin investing and why Abbott Labs (NYS: ABT) and ExxonMobil (NYS: XOM) are the first two stocks she decided to buy on her financial journey.

Looking for our prediction for 2012? Check out The Motley Fool's brand-new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.

At the time this article was published Eric Bleeker does not own shares of the companies listed above. Maggie Muraca owns shares of Abbott Labs and ExxonMobil. The Motley Fool owns shares of Johnson & Johnson and Abbott Labs.Motley Fool newsletter serviceshave recommended buying shares of Abbott Labs and Johnson & Johnson, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners